Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 3/2019

28.10.2019

Vasopressin and Copeptin in health and disease

verfasst von: Mirjam Christ-Crain

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Arginine Vasopressin (AVP) and copeptin derive from the same precursor molecule. Due to the equimolar secretion, copeptin responds as rapidly as AVP to osmotic, hemodynamic and unspecific stress-related stimuli and both peptides show a very strong correlation. The physiological functions of AVP are homeostasis of fluid balance, vascular tonus and regulation of the endocrine stress response. In contrast, the exact function of copeptin remains unknown. Since copeptin, in contrast to AVP, can easily be measured with a sandwich immunoassay, its main function so far that it indirectly indicates the amount of AVP in the circulation. Copeptin has emerged as a useful measure in different diseases. On one hand, through its characteristics as a marker of stress, it provides a unique measure of the individual stress burden. As such, it is a prognostic marker in different acute diseases such as ischemic stroke or myocardial infarction. On the other side, it has emerged as a promising marker in the diagnosis of AVP-dependent fluid disorders. Copeptin reliably differentiates various entities of the polyuria polydipsia syndrome; baseline levels >20 pmol/L without prior fluid deprivation identify patients with nephrogenic diabetes insipidus, whereas levels measured upon osmotic stimulation with hypertonic saline or upon non-osmotic stimulation with arginine differentiate primary polydipsia from central diabetes insipidus. In patients with hyponatremia, low levels of copeptin together with low urine osmolality identify patients with primary polydipsia, but copeptin levels overlap in all other causes of hyponatremia, limiting its diagnostic use in hyponatremia. Copeptin has also been put forward as predictive marker for autosomal dominant polycystic kidney disease and for diabetes mellitus, but more studies are needed to confirm these findings.
Literatur
1.
Zurück zum Zitat Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. Clin Chem. 1999;45:98–103.PubMed Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. Clin Chem. 1999;45:98–103.PubMed
2.
Zurück zum Zitat Balanescu S, et al. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab. 2011;96:1046–52.PubMed Balanescu S, et al. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab. 2011;96:1046–52.PubMed
3.
Zurück zum Zitat Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112–9.PubMed Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112–9.PubMed
4.
Zurück zum Zitat Richter D, Schmale H. The structure of the precursor to arginine-vasopressin: a model preprohormone. Prog Brain Res. 1983;60:227–33.PubMed Richter D, Schmale H. The structure of the precursor to arginine-vasopressin: a model preprohormone. Prog Brain Res. 1983;60:227–33.PubMed
5.
Zurück zum Zitat Land H, Schutz G, Schmale H, Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature. 1982;295:299–303.PubMed Land H, Schutz G, Schmale H, Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature. 1982;295:299–303.PubMed
6.
Zurück zum Zitat Levy B, Chauvet MT. Chauvet, J. & Acher, R. Ontogeny of bovine neurohypophysial hormone precursors. II. Foetal copeptin, the third domain of the vasopressin precursor. Int J Pept Protein Res. 1986;27:320–4.PubMed Levy B, Chauvet MT. Chauvet, J. & Acher, R. Ontogeny of bovine neurohypophysial hormone precursors. II. Foetal copeptin, the third domain of the vasopressin precursor. Int J Pept Protein Res. 1986;27:320–4.PubMed
7.
Zurück zum Zitat Land H, et al. Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor cDNA. Nature. 1983;302:342–4.PubMed Land H, et al. Deduced amino acid sequence from the bovine oxytocin-neurophysin I precursor cDNA. Nature. 1983;302:342–4.PubMed
8.
Zurück zum Zitat Acher R, Chauvet J, Rouille Y. Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport. J Mol Neurosci. 2002;18:223–8.PubMed Acher R, Chauvet J, Rouille Y. Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport. J Mol Neurosci. 2002;18:223–8.PubMed
9.
Zurück zum Zitat de Bree FM, Burbach JP. Structure-function relationships of the vasopressin prohormone domains. Cell Mol Neurobiol. 1998;18:173–91.PubMed de Bree FM, Burbach JP. Structure-function relationships of the vasopressin prohormone domains. Cell Mol Neurobiol. 1998;18:173–91.PubMed
10.
Zurück zum Zitat Vandesande F, Dierickx K. Identification of the vasopressin producing and of the oxytocin producing neurons in the hypothalamic magnocellular neurosecretroy system of the rat. Cell Tissue Res. 1975;164:153–62.PubMed Vandesande F, Dierickx K. Identification of the vasopressin producing and of the oxytocin producing neurons in the hypothalamic magnocellular neurosecretroy system of the rat. Cell Tissue Res. 1975;164:153–62.PubMed
11.
Zurück zum Zitat Gillies GE, Linton EA, Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature. 1982;299:355–7.PubMed Gillies GE, Linton EA, Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature. 1982;299:355–7.PubMed
12.
Zurück zum Zitat Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983;305:325–7.PubMed Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature. 1983;305:325–7.PubMed
13.
Zurück zum Zitat Nathanson MH, et al. Mechanisms of subcellular cytosolic Ca2+ signaling evoked by stimulation of the vasopressin V1a receptor. J Biol Chem. 1992;267:23282–9.PubMed Nathanson MH, et al. Mechanisms of subcellular cytosolic Ca2+ signaling evoked by stimulation of the vasopressin V1a receptor. J Biol Chem. 1992;267:23282–9.PubMed
14.
Zurück zum Zitat Jard, S. Vasopressin and oxytocin receptors: an overview. In: Imura H, Shizume K, eds. Progress in Endocrinology. Amsterdam: Elsevier Science Publishers, 1183 (1988). Jard, S. Vasopressin and oxytocin receptors: an overview. In: Imura H, Shizume K, eds. Progress in Endocrinology. Amsterdam: Elsevier Science Publishers, 1183 (1988).
15.
Zurück zum Zitat Nagy G, Mulchahey JJ, Smyth DG, Neill JD. The glycopeptide moiety of vasopressin-neurophysin precursor is neurohypophysial prolactin releasing factor. Biochem Biophys Res Commun. 1988;151:524–9.PubMed Nagy G, Mulchahey JJ, Smyth DG, Neill JD. The glycopeptide moiety of vasopressin-neurophysin precursor is neurohypophysial prolactin releasing factor. Biochem Biophys Res Commun. 1988;151:524–9.PubMed
16.
Zurück zum Zitat Hyde JF, North WG, Ben-Jonathan N. The vasopressin-associated glycopeptide is not a prolactin-releasing factor: studies with lactating Brattleboro rats. Endocrinology. 1989;125:35–40.PubMed Hyde JF, North WG, Ben-Jonathan N. The vasopressin-associated glycopeptide is not a prolactin-releasing factor: studies with lactating Brattleboro rats. Endocrinology. 1989;125:35–40.PubMed
17.
Zurück zum Zitat Barat C, Simpson L, Breslow E. Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry. 2004;43:8191–203.PubMed Barat C, Simpson L, Breslow E. Properties of human vasopressin precursor constructs: inefficient monomer folding in the absence of copeptin as a potential contributor to diabetes insipidus. Biochemistry. 2004;43:8191–203.PubMed
18.
Zurück zum Zitat Parodi AJ. Protein glucosylation and its role in protein folding. Annu Rev Biochem. 2000;69:69–93.PubMed Parodi AJ. Protein glucosylation and its role in protein folding. Annu Rev Biochem. 2000;69:69–93.PubMed
19.
Zurück zum Zitat Schrag JD, Procopio DO, Cygler M, Thomas DY, Bergeron JJ. Lectin control of protein folding and sorting in the secretory pathway. Trends Biochem Sci. 2003;28:49–57.PubMed Schrag JD, Procopio DO, Cygler M, Thomas DY, Bergeron JJ. Lectin control of protein folding and sorting in the secretory pathway. Trends Biochem Sci. 2003;28:49–57.PubMed
20.
Zurück zum Zitat Bhandari SS, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009;116:257–63. Bhandari SS, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009;116:257–63.
21.
Zurück zum Zitat Darzy KH, Dixit KC, Shalet SM, Morgenthaler NG, Brabant G. Circadian secretion pattern of copeptin, the C-terminal vasopressin precursor fragment. Clin Chem. 2010;56:1190–1.PubMed Darzy KH, Dixit KC, Shalet SM, Morgenthaler NG, Brabant G. Circadian secretion pattern of copeptin, the C-terminal vasopressin precursor fragment. Clin Chem. 2010;56:1190–1.PubMed
22.
Zurück zum Zitat Walti C, Siegenthaler J, Christ-Crain M. Copeptin levels are independent of ingested nutrient type after standardised meal administration--the CoMEAL study. Biomarkers. 2014;19:557–62.PubMed Walti C, Siegenthaler J, Christ-Crain M. Copeptin levels are independent of ingested nutrient type after standardised meal administration--the CoMEAL study. Biomarkers. 2014;19:557–62.PubMed
23.
Zurück zum Zitat Puder JJ, et al. Menstrual cycle symptoms are associated with changes in low-grade inflammation. Eur J Clin Investig. 2006;36:58–64. Puder JJ, et al. Menstrual cycle symptoms are associated with changes in low-grade inflammation. Eur J Clin Investig. 2006;36:58–64.
24.
Zurück zum Zitat Szinnai G, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007;92:3973–8.PubMed Szinnai G, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007;92:3973–8.PubMed
25.
Zurück zum Zitat Wun T. Vasopressin and platelets: a concise review. Platelets. 1997;8:15–22.PubMed Wun T. Vasopressin and platelets: a concise review. Platelets. 1997;8:15–22.PubMed
26.
Zurück zum Zitat Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension. 1983;5:I129–38.PubMed Preibisz JJ, Sealey JE, Laragh JH, Cody RJ, Weksler BB. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension. 1983;5:I129–38.PubMed
27.
Zurück zum Zitat Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest. 1976;57:1109–16.PubMedPubMedCentral Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest. 1976;57:1109–16.PubMedPubMedCentral
28.
Zurück zum Zitat Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973;52:2340–52.PubMedPubMedCentral Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973;52:2340–52.PubMedPubMedCentral
29.
Zurück zum Zitat Fenske W, Allolio B. Clinical review: Current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review. J Clin Endocrinol Metab. 2012;97:3426–37.PubMed Fenske W, Allolio B. Clinical review: Current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review. J Clin Endocrinol Metab. 2012;97:3426–37.PubMed
30.
Zurück zum Zitat Robertson GL. Posterior pituitary. In: Felig P, Baxter J, Frohman L, editors. Endocrinology and metabolism. New York: McGraw-Hill; 385. p. 432–1995. Robertson GL. Posterior pituitary. In: Felig P, Baxter J, Frohman L, editors. Endocrinology and metabolism. New York: McGraw-Hill; 385. p. 432–1995.
31.
Zurück zum Zitat Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003;17:471–503.PubMed Verbalis JG. Disorders of body water homeostasis. Best Pract Res Clin Endocrinol Metab. 2003;17:471–503.PubMed
32.
Zurück zum Zitat Fenske W, et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome--revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab. 2011;96:1506–15.PubMed Fenske W, et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome--revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab. 2011;96:1506–15.PubMed
33.
Zurück zum Zitat Cadnapaphornchai MA, et al. Effect of primary polydipsia on aquaporin and sodium transporter abundance. Am J Physiol Ren Physiol. 2003;285:F965–71. Cadnapaphornchai MA, et al. Effect of primary polydipsia on aquaporin and sodium transporter abundance. Am J Physiol Ren Physiol. 2003;285:F965–71.
34.
35.
Zurück zum Zitat Fenske W, et al. Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics. J Clin Endocrinol Metab. 2008;93:2991–7.PubMed Fenske W, et al. Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics. J Clin Endocrinol Metab. 2008;93:2991–7.PubMed
36.
Zurück zum Zitat Fenske W, et al. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009;94:123–9.PubMed Fenske W, et al. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009;94:123–9.PubMed
37.
Zurück zum Zitat Berliner RW, Davidson DG. Production of hypertonic urine in the absence of pituitary antidiuretic hormone. J Clin Invest. 1957;36:1416–27.PubMedPubMedCentral Berliner RW, Davidson DG. Production of hypertonic urine in the absence of pituitary antidiuretic hormone. J Clin Invest. 1957;36:1416–27.PubMedPubMedCentral
38.
Zurück zum Zitat Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med. 1970;73:721–9.PubMed Miller M, Dalakos T, Moses AM, Fellerman H, Streeten DH. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med. 1970;73:721–9.PubMed
39.
Zurück zum Zitat Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med. 1981;305:1539–46.PubMed Zerbe RL, Robertson GL. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med. 1981;305:1539–46.PubMed
40.
Zurück zum Zitat Baylis PH. Diabetes insipidus. J R Coll Physicians Lond. 1998;32:108–11.PubMed Baylis PH. Diabetes insipidus. J R Coll Physicians Lond. 1998;32:108–11.PubMed
41.
Zurück zum Zitat Baylis PH, Gaskill MB, Robertson GL. Vasopressin secretion in primary polydipsia and cranial diabetes insipidus. Q J Med. 1981;50:345–58.PubMed Baylis PH, Gaskill MB, Robertson GL. Vasopressin secretion in primary polydipsia and cranial diabetes insipidus. Q J Med. 1981;50:345–58.PubMed
42.
Zurück zum Zitat Czaczkes JW, Kleeman CR. The effect of various states of hydration and the plasma concentration on the turnover of antidiuretic hormone in mammals. J Clin Invest. 1964;43:1649–58.PubMedPubMedCentral Czaczkes JW, Kleeman CR. The effect of various states of hydration and the plasma concentration on the turnover of antidiuretic hormone in mammals. J Clin Invest. 1964;43:1649–58.PubMedPubMedCentral
43.
Zurück zum Zitat Katan M, et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab. 2007;92:2640–3.PubMed Katan M, et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab. 2007;92:2640–3.PubMed
44.
Zurück zum Zitat Winzeler, B. et al. Postoperative copeptin concentration predicts diabetes insipidus after pituitary surgery. J Clin Endocrinol Metab, jc20144527 (2015). Winzeler, B. et al. Postoperative copeptin concentration predicts diabetes insipidus after pituitary surgery. J Clin Endocrinol Metab, jc20144527 (2015).
45.
Zurück zum Zitat Timper, K. et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: A prospective multicenter study. J Clin Endocrinol Metab, jc20144507 (2015). Timper, K. et al. Diagnostic accuracy of copeptin in the differential diagnosis of the polyuria-polydipsia syndrome: A prospective multicenter study. J Clin Endocrinol Metab, jc20144507 (2015).
46.
Zurück zum Zitat Fenske W, et al. A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. N Engl J Med. 2018;379:428–39.PubMed Fenske W, et al. A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. N Engl J Med. 2018;379:428–39.PubMed
47.
Zurück zum Zitat Nair NP, et al. Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine. Prog Neuro-Psychopharmacol Biol Psychiatry. 1985;9:633–7. Nair NP, et al. Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine. Prog Neuro-Psychopharmacol Biol Psychiatry. 1985;9:633–7.
48.
Zurück zum Zitat Merimee TJ, Rabinowtitz D, Fineberg SE. Arginine-initiated release of human growth hormone. Factors modifying the response in normal man. N Engl J Med. 1969;280:1434–8.PubMed Merimee TJ, Rabinowtitz D, Fineberg SE. Arginine-initiated release of human growth hormone. Factors modifying the response in normal man. N Engl J Med. 1969;280:1434–8.PubMed
49.
Zurück zum Zitat Alba-Roth J, Muller OA, Schopohl J, von Werder K. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab. 1988;67:1186–9.PubMed Alba-Roth J, Muller OA, Schopohl J, von Werder K. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab. 1988;67:1186–9.PubMed
50.
Zurück zum Zitat Winzeler B, et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet. 2019. Winzeler B, et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet. 2019.
51.
Zurück zum Zitat Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119:S30–5.PubMed Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119:S30–5.PubMed
52.
Zurück zum Zitat Tang WW, Kaptein EM, Feinstein EI, Massry SG. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med. 1993;94:169–74.PubMed Tang WW, Kaptein EM, Feinstein EI, Massry SG. Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med. 1993;94:169–74.PubMed
53.
Zurück zum Zitat Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120:S1–21.PubMed Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120:S1–21.PubMed
54.
Zurück zum Zitat Chung HM, Kluge R, Schrier RW, Anderson RJ. Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med. 1987;83:905–8.PubMed Chung HM, Kluge R, Schrier RW, Anderson RJ. Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med. 1987;83:905–8.PubMed
55.
Zurück zum Zitat Verbalis JG, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126:S1–42.PubMed Verbalis JG, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126:S1–42.PubMed
56.
Zurück zum Zitat Schrier RW, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.PubMed Schrier RW, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.PubMed
57.
Zurück zum Zitat Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:71.e1–8. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:71.e1–8.
58.
Zurück zum Zitat Verbalis JG, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res. 2010;25:554–63.PubMed Verbalis JG, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res. 2010;25:554–63.PubMed
59.
Zurück zum Zitat Fenske W, Maier SK, Blechschmidt A, Allolio B, Stork S. Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study. Am J Med. 2010;123:652–7.PubMed Fenske W, Maier SK, Blechschmidt A, Allolio B, Stork S. Utility and limitations of the traditional diagnostic approach to hyponatremia: a diagnostic study. Am J Med. 2010;123:652–7.PubMed
60.
Zurück zum Zitat Nigro N, et al. Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: 'The Co-MED Study'. Clin Endocrinol. 2017;86:456–62. Nigro N, et al. Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: 'The Co-MED Study'. Clin Endocrinol. 2017;86:456–62.
61.
Zurück zum Zitat Verbalis JG, et al. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion. Am J Med. 2016;129:537 e9–537 e23. Verbalis JG, et al. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion. Am J Med. 2016;129:537 e9–537 e23.
62.
Zurück zum Zitat Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957;23:529–42.PubMed Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957;23:529–42.PubMed
63.
Zurück zum Zitat Zerbe R, Stropes L, Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med. 1980;31:315–27.PubMed Zerbe R, Stropes L, Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med. 1980;31:315–27.PubMed
64.
Zurück zum Zitat Fenske WK, et al. A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis. J Am Soc Nephrol. 2014;25:2376–83.PubMedPubMedCentral Fenske WK, et al. A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis. J Am Soc Nephrol. 2014;25:2376–83.PubMedPubMedCentral
65.
Zurück zum Zitat Hirata Y, Matsukura S, Imura H, Yakura T, Ihjima S. Two cases of multiple hormone-producing small cell carcinoma of the lung: coexistence of tumor ADH, ACTH, and beta-MSH. Cancer. 1976;38:2575–82.PubMed Hirata Y, Matsukura S, Imura H, Yakura T, Ihjima S. Two cases of multiple hormone-producing small cell carcinoma of the lung: coexistence of tumor ADH, ACTH, and beta-MSH. Cancer. 1976;38:2575–82.PubMed
66.
Zurück zum Zitat List AF, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol. 1986;4:1191–8.PubMed List AF, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol. 1986;4:1191–8.PubMed
67.
Zurück zum Zitat Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med. 1995;238:97–110.PubMed Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med. 1995;238:97–110.PubMed
68.
Zurück zum Zitat Burst V, et al. Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study. Support Care Cancer. 2017;25:2275–83.PubMedPubMedCentral Burst V, et al. Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study. Support Care Cancer. 2017;25:2275–83.PubMedPubMedCentral
69.
Zurück zum Zitat Schuetz P, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14:R106.PubMedPubMedCentral Schuetz P, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14:R106.PubMedPubMedCentral
70.
Zurück zum Zitat Katan M, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66:799–808.PubMed Katan M, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol. 2009;66:799–808.PubMed
71.
Zurück zum Zitat Reichlin T, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54:60–8.PubMed Reichlin T, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54:60–8.PubMed
72.
Zurück zum Zitat Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly. 2010;140:w13101.PubMed Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly. 2010;140:w13101.PubMed
73.
Zurück zum Zitat Morgenthaler, N.G. et al. Copeptin, a Stable Peptide of the Arginine Vasopressin Precursor, Is Elevated in Hemorrhagic and Septic Shock. Shock (2007). Morgenthaler, N.G. et al. Copeptin, a Stable Peptide of the Arginine Vasopressin Precursor, Is Elevated in Hemorrhagic and Septic Shock. Shock (2007).
74.
Zurück zum Zitat Lindner KH, et al. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology. 1992;77:662–8.PubMed Lindner KH, et al. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiology. 1992;77:662–8.PubMed
75.
Zurück zum Zitat Zhang Q, Dong G, Zhao X, Wang M, Li CS. Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department. Intensive Care Med. 2014;40:1499–508.PubMed Zhang Q, Dong G, Zhao X, Wang M, Li CS. Prognostic significance of hypothalamic-pituitary-adrenal axis hormones in early sepsis: a study performed in the emergency department. Intensive Care Med. 2014;40:1499–508.PubMed
76.
Zurück zum Zitat Muller B, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Investig. 2007;37:145–52. Muller B, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Investig. 2007;37:145–52.
77.
Zurück zum Zitat Kolditz M, Ewig S, Hoffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J. 2013;41:974–84.PubMed Kolditz M, Ewig S, Hoffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J. 2013;41:974–84.PubMed
78.
Zurück zum Zitat Stolz D, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131:1058–67.PubMed Stolz D, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131:1058–67.PubMed
79.
Zurück zum Zitat Stoiser B, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Investig. 2006;36:771–8. Stoiser B, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Investig. 2006;36:771–8.
80.
Zurück zum Zitat Gegenhuber A, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007;13:42–9.PubMed Gegenhuber A, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007;13:42–9.PubMed
81.
Zurück zum Zitat Zhong Y, et al. Copeptin in heart failure: Review and meta-analysis. Clin Chim Acta. 2017;475:36–43.PubMed Zhong Y, et al. Copeptin in heart failure: Review and meta-analysis. Clin Chim Acta. 2017;475:36–43.PubMed
82.
Zurück zum Zitat Khan SQ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115:2103–10.PubMed Khan SQ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115:2103–10.PubMed
83.
Zurück zum Zitat Wildi K, et al. Comparison of fourteen rule-out strategies for acute myocardial infarction. Int J Cardiol. 2019;283:41–7.PubMed Wildi K, et al. Comparison of fourteen rule-out strategies for acute myocardial infarction. Int J Cardiol. 2019;283:41–7.PubMed
84.
Zurück zum Zitat Fassbender K, Schmidt R, Mossner R. Daffertshofer, M. & Hennerici, M. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke. 1994;25:1105–8.PubMed Fassbender K, Schmidt R, Mossner R. Daffertshofer, M. & Hennerici, M. Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute stroke. Relation to acute confusional state, extent of brain damage, and clinical outcome. Stroke. 1994;25:1105–8.PubMed
85.
Zurück zum Zitat Johansson A, Olsson T, Carlberg B, Karlsson K, Fagerlund M. Hypercortisolism after stroke--partly cytokine-mediated? J Neurol Sci. 1997;147:43–7.PubMed Johansson A, Olsson T, Carlberg B, Karlsson K, Fagerlund M. Hypercortisolism after stroke--partly cytokine-mediated? J Neurol Sci. 1997;147:43–7.PubMed
86.
Zurück zum Zitat Slowik A, et al. Hypercortisolemia in acute stroke is related to the inflammatory response. J Neurol Sci. 2002;196:27–32.PubMed Slowik A, et al. Hypercortisolemia in acute stroke is related to the inflammatory response. J Neurol Sci. 2002;196:27–32.PubMed
87.
Zurück zum Zitat Johansson A, Ahren B, Nasman B, Carlstrom K, Olsson T. Cortisol axis abnormalities early after stroke--relationships to cytokines and leptin. J Intern Med. 2000;247:179–87.PubMed Johansson A, Ahren B, Nasman B, Carlstrom K, Olsson T. Cortisol axis abnormalities early after stroke--relationships to cytokines and leptin. J Intern Med. 2000;247:179–87.PubMed
88.
Zurück zum Zitat De Marchis GM, et al. A novel biomarker-based prognostic score in acute ischemic stroke: The CoRisk score. Neurology. 2019;92:e1517–25.PubMed De Marchis GM, et al. A novel biomarker-based prognostic score in acute ischemic stroke: The CoRisk score. Neurology. 2019;92:e1517–25.PubMed
89.
Zurück zum Zitat Siegenthaler J, Walti C, Urwyler SA, Schuetz P, Christ-Crain M. Copeptin concentrations during psychological stress: the PsyCo study. Eur J Endocrinol. 2014;171:737–42.PubMed Siegenthaler J, Walti C, Urwyler SA, Schuetz P, Christ-Crain M. Copeptin concentrations during psychological stress: the PsyCo study. Eur J Endocrinol. 2014;171:737–42.PubMed
90.
Zurück zum Zitat Urwyler, S.A., Schuetz, P., Sailer, C. & Christ-Crain, M. Copeptin as a stress marker prior and after a written examination - the CoEXAM study. Stress, 1–4 (2015). Urwyler, S.A., Schuetz, P., Sailer, C. & Christ-Crain, M. Copeptin as a stress marker prior and after a written examination - the CoEXAM study. Stress, 1–4 (2015).
91.
Zurück zum Zitat Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287–301.PubMed Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287–301.PubMed
92.
Zurück zum Zitat Schrier RW, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25:2399–418.PubMedPubMedCentral Schrier RW, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25:2399–418.PubMedPubMedCentral
93.
Zurück zum Zitat Meijer E, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:361–8.PubMedPubMedCentral Meijer E, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:361–8.PubMedPubMedCentral
94.
Zurück zum Zitat Boertien WE, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis. 2013;61:420–9.PubMed Boertien WE, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis. 2013;61:420–9.PubMed
95.
96.
Zurück zum Zitat Boertien WE, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia. 2013;56:1680–8.PubMed Boertien WE, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia. 2013;56:1680–8.PubMed
97.
Zurück zum Zitat Pikkemaat M, Melander O, Bengtsson Bostrom K. Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register. J Diabetes Complicat. 2015;29:1062–5. Pikkemaat M, Melander O, Bengtsson Bostrom K. Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register. J Diabetes Complicat. 2015;29:1062–5.
98.
Zurück zum Zitat Velho G, et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care. 2013;36:3639–45.PubMedPubMedCentral Velho G, et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care. 2013;36:3639–45.PubMedPubMedCentral
99.
Zurück zum Zitat Muscogiuri G, et al. Water intake keeps type 2 diabetes away? Focus on copeptin. Endocrine. 2018;62:292–8.PubMed Muscogiuri G, et al. Water intake keeps type 2 diabetes away? Focus on copeptin. Endocrine. 2018;62:292–8.PubMed
Metadaten
Titel
Vasopressin and Copeptin in health and disease
verfasst von
Mirjam Christ-Crain
Publikationsdatum
28.10.2019
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 3/2019
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-019-09509-9

Weitere Artikel der Ausgabe 3/2019

Reviews in Endocrine and Metabolic Disorders 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.